Results 41 to 50 of about 2,988 (212)
Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond
ParasitologyHuman alveolar echinococcosis is a hard-to-treat and largely untreated parasitic disease with high associated health care costs. The current antiparasitic treatment for alveolar echinococcosis relies exclusively on albendazole, which does not act ...
Weisi Wang +11 more
doaj +1 more source
Advances in Pharmacological Sciences, 2009 In the in vivo experiments on anaesthetized sheep, it was presently examined whether muscarinic receptor antagonists with diverse selectivity affect the release of VIP in response to electrical stimulation of the parasympathetic chorda tympanic nerve ...
Anders T. Ryberg +2 more
doaj +1 more source
Are we doing enough for the patient with myopia? A literature review
British and Irish Orthoptic Journal, 2011 Aim: Myopia is one of the most common eye conditions and often has a progressive nature. With higher degrees come greater risks of visual disability; however, typically no treatment is offered clinically to tackle myopic progression. This review aims to
Marina Parker, Anna R. O’connor
doaj +1 more source
Frontiers in Cellular Neuroscience, 2022 We established a novel brain slice assay to test the ability of acetylcholinesterase (AChE) reactivators to prevent ACh-induced M1 muscarinic acetylcholine receptor (mAChR) dependent hyperexcitability observed after exposure to the organophosphate (OP ...
Jeffrey S. Thinschmidt +4 more
doaj +1 more source
Methods of preventing and retarding the progression of myopia
Journal of Education, Health and Sport, 2019 Myopia is an increasing problem worldwide. Its prevalence is predicted to over 4 billion of people in 2050, what would be almost 50% of the population.
Ewa Grudzińska +2 more
doaj +3 more sources
Frontiers in Neuroscience, 2018 The muscarinic acetylcholine type 1 receptor (M1R) is a metabotropic G protein-coupled receptor. Knockout of M1R or exposure to selective or specific receptor antagonists elevates neurite outgrowth in adult sensory neurons and is therapeutic in diverse ...
Mohammad G. Sabbir +3 more
doaj +1 more source
The effects of the antimuscarinic drugs pirenzepine and atropine on plasma portal levels of somatostatin and gastrin in the dog [PDF]
, 1987 The effects of the antimuscarinic drugs pirenzepine and atropine on somatostatin and gastrin portal levels under basal conditions and during bethanechol infusion have been investigated in anesthetized dogs. Iv bolus administration of pirenzepine (1 mg/kg)
Soldani, G. +5 more
core +1 more source
Clinical and Translational Science, Volume 19, Issue 5, May 2026.ABSTRACT Genetic variants in drug transporter genes shape the interindividual variability in drug response. However, their functional interpretation has remained limited due to the substrate dependence of variant effects. Existing predictors are substrate‐agnostic and cannot capture how a single amino acid change differentially affects transport across
Yoomi Park +4 more
wiley +1 more source
Pirenzepine-sensitive muscarinic receptors regulate gastric somatostatin and gastrin
, 1985 Pirenzepine, a newly described antagonist of selective muscarinic receptors (M1), has been shown to be a potent inhibitor of acid secretion. To determine whether this property of pirenzepine can be explained in part by its actions on hormones regulating
A. H. Soll +4 more
core +1 more source
EXPLORING ANTIHYPERTENSIVE DRUG LEADS FROM BLIGHIA SAPIDA K. D. KOENIG VIA GC-MS AND IN SILICO APPROACHES [PDF]
Journal of Plant DevelopmentGlobally, hypertension is a leading cause of cardiovascular diseases that account for around 17 million deaths. Despite more studies and management measures, the cause of hypertension is barely unknown, auxiliary antihypertensive medications have some ...
Comfort Titilayomi SENJOBI +10 more
doaj +1 more source